Trajectories of Prescription Opioid Utilization During Pregnancy Among Prepregnancy Chronic Users and Risk of Neonatal Opioid Withdrawal Syndrome. Issue 1 (13th October 2021)

• Record Type: Journal Article
• Authors: Straub, Loreen; Huybrechts, Krista F; Hernández-Díaz, Sonia; Zhu, Yanmin; Vine, Seanna; Desai, Rishi J; Gray, Kathryn J; Bateman, Brian T
• Is Part Of: American journal of epidemiology. Volume 191:Issue 1(2022)
• Page Start: 208
• Page End: 219
• Publication Date: 2021-10-13
• Subjects: chronic opioid use -- drug withdrawal -- neonatal abstinence syndrome -- neonatal opioid withdrawal syndrome -- opioid dose trajectories -- opioids -- opioid use patterns -- pregnancy; Epidemiology -- Periodicals; Public health -- Periodicals; 614.4
• DOI: 10.1093/aje/kwab249
• Languages: English
• ISSNs: 0002-9262

Abstract

Abstract: Little is known about the impact of dose, duration, and timing of prenatal prescription opioid exposure on the risk of neonatal opioid withdrawal syndrome (NOWS). Using a cohort of 18, 869 prepregnancy chronic opioid users nested within the 2000–2014 Medicaid Analytic eXtract, we assessed average opioid dosage within biweekly gestational age intervals, created group-based trajectory models, and evaluated the association between trajectory groups and NOWS risk. Women were grouped into 6 distinct opioid use trajectories which, based on observed patterns, were categorized as 1) continuous very low-dose use, 2) continuous low-dose use, 3) initial moderate-dose use with a gradual decrease to very low-dose/no use, 4) initial high-dose use with a gradual decrease to very low-dose use, 5) continuous moderate-dose use, and 6) continuous high-dose use. Absolute risk of NOWS per 1, 000 infants was 7.7 for group 1 (reference group), 28.8 for group 2 (relative risk (RR) = 3.7, 95% confidence interval (CI): 2.8, 5.0), 16.5 for group 3 (RR = 2.1, 95% CI: 1.5, 3.1), 64.9 for group 4 (RR = 8.4, 95% CI: 5.6, 12.6), 77.3 for group 5 (RR = 10.0, 95% CI: 7.5, 13.5), and 172.4 for group 6 (RR = 22.4, 95% CI: 16.1, 31.2). Trajectory models—which capture information on dose, duration, and timing of exposure—are useful for gaining insight into clinically relevant groupings to evaluate the risk of prenatal opioid exposure.